Ceva spends $23M to upgrade its sterile products plant in France

Ceva's Libourne, France, headquarters--Courtesy of Ceva Santé Animale

Ceva Santé Animale, a global veterinary health group, recently inaugurated its €18 million ($23 million) renovation and extension of its sterile products plant, which will increase injectable drug production capacity.

The plant is located at the company's headquarters in Libourne, France. The facility now has the capacity to produce 18 million vials a year, the company said in a press release. The first orders from the plant are expected to ship to China this week.

"This project was an essential step to support our ambitions and secure the plant's competitive edge," Emmanuel Coudré, the Libourne site director, said in a statement.

In August, the company committed to spending $8.3 million to expand its U.S. operations and beef up its facility in Lenexa, KS. In 2005, Ceva bought Biomune and spent $7 million on expanding that company's former R&D facility. Ceva was founded in 1999, when the former Sanofi-Aventis subsidiary completed the first of four leveraged buyouts.

Originally focused mostly on poultry, in the past year the company has announced plans to expand into the equine and swine markets.

- see the release

Special Report: Top 10 animal health companies of 2013 - Ceva Animal Health